Organon Q2 revenues $1.585B (-1% as-reported, +5% ex-FX); adj EPS $1.25; FY guidance narrowed

Organon & Co.

2022-Q2 EPS reported $2.28 revenue$3,152,000,000

Q2 revenues $1,585M, down 1% as-reported but up 5% ex-FX vs Q2 2021; diluted EPS $0.92, adj diluted EPS $1.25 (both include -$0.30 IPR&D).
Adjusted EBITDA $512M (32.3% margin), inclusive of $97M acquired IPR&D and milestones.
Board declares quarterly dividend $0.28/share (unchanged).
Full-year 2022 revenue guidance narrowed to $6.1B-$6.3B; adj EBITDA margin 32%-34% reflecting FX and IPR&D.
Biosimilars revenue +42% ex-FX; Established Brands +4% ex-FX; Women's Health +1% ex-FX.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.